Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022

SELL
$1.22 - $1.77 $1,764 - $2,559
-1,446 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$1.39 - $5.58 $144 - $580
-104 Reduced 6.71%
1,446 $2,000
Q3 2021

Nov 10, 2021

BUY
$4.71 - $5.92 $2,826 - $3,552
600 Added 63.16%
1,550 $7,000
Q2 2021

Aug 05, 2021

SELL
$5.32 - $6.53 $7,086 - $8,697
-1,332 Reduced 58.37%
950 $6,000
Q1 2021

Apr 28, 2021

SELL
$2.75 - $6.57 $25,558 - $61,061
-9,294 Reduced 80.29%
2,282 $12,000
Q4 2020

Feb 04, 2021

BUY
$1.38 - $3.01 $13,946 - $30,419
10,106 Added 687.48%
11,576 $30,000
Q3 2020

Nov 10, 2020

SELL
$1.58 - $4.77 $3,346 - $10,102
-2,118 Reduced 59.03%
1,470 $2,000
Q2 2020

Aug 07, 2020

BUY
$3.74 - $6.28 $6,455 - $10,839
1,726 Added 92.7%
3,588 $16,000
Q1 2020

May 13, 2020

SELL
$2.33 - $12.98 $4,284 - $23,870
-1,839 Reduced 49.69%
1,862 $7,000
Q4 2019

Feb 04, 2020

SELL
$6.75 - $11.15 $2,281 - $3,768
-338 Reduced 8.37%
3,701 $40,000
Q3 2019

Nov 08, 2019

BUY
$8.57 - $10.72 $2,896 - $3,623
338 Added 9.13%
4,039 $35,000
Q1 2019

May 08, 2019

SELL
$5.81 - $9.37 $3,979 - $6,418
-685 Reduced 15.62%
3,701 $29,000
Q4 2018

Feb 13, 2019

BUY
$5.75 - $21.85 $10,304 - $39,155
1,792 Added 69.08%
4,386 $28,000
Q3 2018

Nov 01, 2018

BUY
$16.81 - $24.58 $5,311 - $7,767
316 Added 13.87%
2,594 $59,000
Q2 2018

Aug 08, 2018

BUY
$18.6 - $24.94 $6,807 - $9,128
366 Added 19.14%
2,278 $44,000
Q1 2018

May 08, 2018

BUY
$20.86 - $26.6 $27,097 - $34,553
1,299 Added 211.91%
1,912 $44,000
Q4 2017

Feb 02, 2018

BUY
$20.9 - $49.36 $11,892 - $28,085
569 Added 1293.18%
613 $15,000
Q3 2017

Nov 13, 2017

BUY
$39.62 - $46.17 $1,743 - $2,031
44
44 $2,000

Others Institutions Holding DBVT

About DBV Technologies S.A.


  • Ticker DBVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,776,992
  • Market Cap $175M
  • Description
  • DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...
More about DBVT
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.